Doc code: IDS

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1 99)

Application Number		10574211			
Filing Date		2007-01-22			
First Named Inventor	Wilfrie	ed Lubisch			
Art Unit		1625			
Examiner Name	Chan	drakumar, Nizal S			
Attorney Docket Number		0480/020919USO2 (139354)			

PTO/SB/08a (01-10)

Examiner Initial* Cite No Patent Number Kind Code* Issue Date Name of Patentee or Applicant of cited Document Pages, Columns, Lines whe Relevant Passages or					U.S.	PATENTS	
2 6596732 B2 2003-07-22 Sanofi-Synthelabo 3 7119086 B2 2006-10-10 Sanofi-Aventis 4 5594023 1997-01-14 Sanofi					Code1 Issue Date Indine of Patentee of Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
3 7119086 B2 2006-10-10 Sanoft-Aventis 4 5594023 1997-01-14 Sanofi		1	5594023		2010-08-17	Abbott GmbH & Co. KG	
4 5594023 1997-01-14 Sanofi		2	6596732	B2	2003-07-22	Sanofi-Synthelabo	
		3	7119086	B2	2006-10-10	Sanofi-Aventis	
5 6090818 2000-07-18 Sanofi-Synthelabo		4	5594023		1997-01-14	Sanofi	
		5	6090818		2000-07-18	Sanofi-Synthelabo	
6 6624164 B2 2003-09-23 Sanofi-Synthelabo		6	6624164	B2	2003-09-23	Sanofi-Synthelabo	
7 6864277 B2 2005-03-08 Sanofi-Synthelabo		7	6864277	B2	2005-03-08	Sanofi-Synthelabo	
f you wish to add additional U.S. Patent citation information please click the Add button.	f you wish	to add	additional U.S. Pater	nt citatio	n information pl	ease click the Add button.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10574211	
Filing Date		2007-01-22	
First Named Inventor	Wilfr	ied Lubisch	
Art Unit		1625	
Examiner Name	Char	ndrakumar, Nizal S	
Attorney Docket Number		0480/020919USO2 (139354)	

	_																		
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	ation	of cited Document		Rele	es,Columns,Lines where vant Passages or Relev res Appear	e vant									
	1	20050070718		2005-03-31		2005-03-31		2005-03-31		Abbott GmbH	& Co. KG								
	2	20070021607		2007-01	-25	Abbott GmbH & Co. KG													
			2008-12-25		2008-12-25		Taisho Pharm	naceutical Co., LTD											
			2003-06	i-19	Sanofi-Synthe	elabo													
	5	20090163492	A1	2009-06	-25	Thorsten Oost													
	6	20090005397	A1	2009-01-01		2009-01-01		2009-01-01		2009-01-01		2009-01-01		2009-01-01	Wilfried Lubise	ch			
	7	20090215790	A1			Wilfried Lubiso	ch												
	8																		
If you wish	to add	l additional U.S. Pub	lished App	olication	citation	information p	please click the Add	butto	n.										
						ENT DOCUM													
		Foreign Document Number ³	Country Code ² i		Kind Code ⁴	Publication Date	Name of Patentee Applicant of cited Document	. 01	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5									

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

	Application Number		10574211			
	Filing Date		2007-01-22			
	First Named Inventor	Wilfrie	ed Lubisch			
	Art Unit		1625			
	Examiner Name Chang		ndrakumar, Nizal S			
Attorney Docket Number		er	0480/020919USO2 (139354)			

 1	2001/98295 UB equivalent 6,864,277 in English is being provided in lieu of	wo	A1	2001-12-27	Sanofi-Synthelabo	
 2	2001/55134 US equivalent 5.624.164 in English is being provided in lieu of a translation	wo	A2	2001-08-02	Sanofi-Synthelabo	
3	2001/55130 US equivalent 2003/114683 in English ia being provided in lieu of a translation	wo	A2	2001-08-02	Sanofi-Synthelabo	
4	2001/64668 US equivalent 6,596,732 in English is being provided in lieu of a translation	wo	A2	2001-09-07	Sanofi-Synthelabo	
5	2003/08407 US equivalent 7,119,086 in English is being provided in lieu of a translation	wo	A2	2003-01-30	Sanofi-Synthelabo	
6	1998/25901 US equivalent 6,090,818 in English is being provided in lieu of a translation	wo	A1	1998-06-18	Sanofi	
7	1993/15051 CA equivalent 2107348 in English is being provided in lieu of a translation.	wo	A1	1993-08-05	Elf Sanofi	
	1995/18105 US equivalent 5,594,023 in English is being provided in lieu of a translation	wo	A1	1995-07-06	Sanofi	
9	2005/030755	wo	A1	2005-04-07	ABBOTT GMBH & CO. KG	
10	2006/100081 US equivalent 2009/215790 in English is being provided in lieu of a translation	wo	A2	2006-09-28	ABBOTT GMBH & CO. KG	
	2006/005609 us equivalent 2009/0005397 in English is being provided in lieu of a translation	wo	A2	2006-01-19	ABBOTT GMBH & CO. KG	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10574211	
Filing Date		2007-01-22	
First Named Inventor	Wilfr	ied Lubisch	
Art Unit		1625	
Examiner Name	Char	ndrakumar, Nizal S	
Attorney Docket Numl	er	0480/020919USO2 (139354)	

				-					
	12	2006/100082 DS equivalent 2009/163492 in English is being provided in lieu of a translation	wo	A2	2006-09-28	ABBOTT GMBH & CO. KG			
	13	2006/080574 us equivalent 2008/318923 in English is being provided in lieu of translation	wo	A1	2006-08-03	Sekiguchi, et al.			
	14	2107348	CA		1992-01-30	Elf-Sanofi			
If you wis	h to a	dd additional Foreign P				ease click the Add buttor	1		
	,		NON-PATE	NT LITE	RATURE DO	CUMENTS			
Examiner Initials*	Cite No	Include name of the ar (book, magazine, journ publisher, city and/or of	nal, serial, symp	osium.	catalog, etc), c	the article (when appropolate, pages(s), volume-is	riate), title of the item sue number(s),	T5	
	1	BARBERIS et al., "Structural bases of vasopressin/osytocin receptor function," J. Endocrinology, 1998, 223-229, Vol. 156, France							
	2	HULME et al., "Quasternary Substituted PDE4 Inhibitors 1: The Synthesis and In Bitro Evaluation of a Novel Series of Oxindoles," Bioorg. & Med. Chem Lett, 1998, 175-178, Vol 8, United Kingdom							
	3	WERSINGER et al., "Vasopressin V 1b Receptor Knockout Reduces Aggressive Behavior in male mice," Molecular Psychiatry, 2002, 975-984, Vol 7, United Kingdom							
	4	GRIEBEL et al., "Anxiolytic-and Antidepressant-like Effects of the Non-peptide Vassopressin V 1b Receptor Antagonist, SSR 149415, Suggest as Innovative Approach for the Treatment of Stress-related Disorders," PNAS, 2002, 6370-6375, Vol. 99, France							
	5	SERRADEIL-LE GAL et a	al., J. Pharm. Exp.	Ther., 2	2002, 1122-1130), Vol. 300, France			
	6	THIBONNIER, M., Exp. C	Opin. Invest. Drugs	s, 1998,	Vol. 7, No. 5, pp	i. 729-740			

Application Number 10574211 Filing Date 2007-01-22

STATEMENT BY APPLICANT	First Named Inventor	Wilfrie	ed Lubisch	
(Not for submission under 37 CFR 1,99)	Art Unit		1625	
,	Examiner Name	Chan	drakumar, Nizal S	
	Attorney Docket, Numb	er	0480/020919/1502 (139354)	

	7 Office Action filed for US Application No. 11/440,569 and mailed 2009-08-04						
	8 Office Action filed for US Application No. 11/440,569 and mailed 2008-12-09						
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button						
			EXAMINER SIGNATURE				
Examiner Signature Date Considered							
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
1 See Kind C	Codes o	f USPT	O Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office	that issued the docume	nt, by the two-letter code (W	PO	

Standard ST.3). § For Japanese patent documents, the indication of the year of the reging of the Emperor preced the seprendial number of the patent document.

§ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

§ Applicant is to place a check mark here if Engish language translation is attached.